|Assessment Status||Rapid Review Complete|
|Indication||Rivaroxaban 10mg daily for the prevention of recurrent venous thromboembolism in patients who have completed at least 6 months anticoagulation therapy for DVT or PE.|
|Rapid review commissioned||20/11/2017|
|Rapid review completed||21/11/2017|
|Rapid review outcome||Full Pharmacoeconomic Assessment Recommended|
A full pharmacoeconomic evaluation is not required as rivaroxaban 10mg is reimbursable under the Community Drug Schemes.